Figure 2.

Summary of IgG responses. (A) Between baseline and dose 1 there was no significant increase in IgG (p = 0.15), however, IgG levels increased dramatically following dose 2 (p = 0.00049) (n = 15 at baseline, n = 14 at dose 1 and dose 2); (B–D) age significantly correlated with final IgG level. Among the 14 subjects for whom we obtained IgG levels post-dose 2, a significant negative linear relationship was observed between age and IgG response (p = 0.018). There were no significant IgG differences observed between the 10 male and 4 female subjects (p = 0.84) nor between subjects receiving the Moderna (n = 6) or Pfizer (n = 8) vaccines (p = 1.0). Sex is indicated by shape, vaccine manufacturer by color, and age by opacity.